GlassScriptPhysician profile
Yatish Goyal
NPI 1023297587
$2,819.42
in general payments reported to CMS, 2019-2025
38 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $279 · 2021: $324 · 2022: $660 · 2023: $195 · 2024: $508 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.41 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Pfizer INC. | $256.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $213.68 | 2019-2024 | Arexvy, Shingrix |
| Silk Road Medical, INC. | $199.99 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Amgen INC. | $175.20 | 2019-2025 | Krystexxa, Repatha |
| Astellas Pharma US INC | $142.14 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $117.98 | 2023-2025 | Rexulti |
| Boston Scientific Corporation | $110.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.64 | 2022 | |
| Amarin Pharma, INC. | $70.23 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $57.19 | 2021-2023 | Gvoke Hypopen |
| Eisai INC. | $52.82 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $41.95 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $31.18 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yatish Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.